De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Kinnate Biopharma Beheer

Beheer criteriumcontroles 2/4

De CEO Kinnate Biopharma's is Nima Farzan, benoemd in Mar2020, heeft een ambtstermijn van 4.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 4.54M, bestaande uit 13.4% salaris en 86.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.005% van de aandelen van het bedrijf, ter waarde $ 5.79K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.9 jaar en 4 jaar.

Belangrijke informatie

Nima Farzan

Algemeen directeur

US$4.5m

Totale compensatie

Percentage CEO-salaris	13.4%
Dienstverband CEO	4.1yrs
Eigendom CEO	0.005%
Management gemiddelde ambtstermijn	3.9yrs
Gemiddelde ambtstermijn bestuur	4yrs

Recente managementupdates

Recent updates

Kinnate Biopharma (NASDAQ:KNTE) Is In A Good Position To Deliver On Growth Plans

Sep 15

Kinnate Biopharma GAAP EPS of -$0.62 beats by $0.03

Aug 11

We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

May 15

Companies Like Kinnate Biopharma (NASDAQ:KNTE) Are In A Position To Invest In Growth

Jan 24

We Think Kinnate Biopharma (NASDAQ:KNTE) Can Afford To Drive Business Growth

Oct 09

Here's Why We're Not Too Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Situation

Jun 22

We're Not Very Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Rate

Mar 03

Kinnate Biopharma earns bulls as IPO quiet period ends

Dec 28

Analyse CEO-vergoeding

Hoe is Nima Farzan's beloning veranderd ten opzichte van Kinnate Biopharma's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Dec 31 2023	US$5m	US$608k	-US$113m
Sep 30 2023	n/a	n/a	-US$127m
Jun 30 2023	n/a	n/a	-US$127m
Mar 31 2023	n/a	n/a	-US$122m
Dec 31 2022	US$4m	US$583k	-US$116m
Sep 30 2022	n/a	n/a	-US$111m
Jun 30 2022	n/a	n/a	-US$105m
Mar 31 2022	n/a	n/a	-US$99m
Dec 31 2021	US$8m	US$558k	-US$90m
Sep 30 2021	n/a	n/a	-US$77m
Jun 30 2021	n/a	n/a	-US$63m
Mar 31 2021	n/a	n/a	-US$49m
Dec 31 2020	US$5m	US$359k	-US$36m

Compensatie versus markt: De totale vergoeding ($USD 4.54M ) Nima } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).

Compensatie versus inkomsten: De vergoeding van Nima is gestegen terwijl het bedrijf verliesgevend is.

CEO

Nima Farzan (47 yo)

4.1yrs

Tenure

US$4,539,776

Compensatie

Mr. Nima Farzan, M.B.A., serves as President and Chief Executive Officer at Kinnate Biopharma Inc. and as a Member of Board of Directors since March 2020. Mr. Farzan had been the Chief Executive Officer at...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Nima Farzan	President	4.1yrs	US$4.54m	0.0046% $ 5.8k
Mark Meltz	COO, General Counsel	4yrs	US$1.70m	0.025% $ 31.7k
Neha Krishnamohan	CFO, Principal Accounting Officer and Executive VP of Corporate Development	2.8yrs	US$2.88m	0.046% $ 58.0k
Robert Kania	Senior Vice President of Research	3.8yrs	geen gegevens	geen gegevens

3.9yrs

Gemiddelde duur

47yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van KNTE wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Nima Farzan	President	4.1yrs	US$4.54m	0.0046% $ 5.8k
Carl Gordon	Independent Director	4.3yrs	US$107.78k	0% $ 0
James Tananbaum	Independent Director	3.8yrs	geen gegevens	0% $ 0
Dean Mitchell	Independent Chair	3.7yrs	US$139.28k	0% $ 0
Laurie Smaldone Alsup	Independent Director	3.7yrs	US$99.28k	0% $ 0
Melissa Epperly	Independent Director	3.5yrs	US$110.28k	0% $ 0
Keith Flaherty	Member of Scientific Advisory Board & Independent Director	4.3yrs	US$103.28k	0.14% $ 175.9k
Luiz Diaz	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
John Iafrate	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Andrew Lowy	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Ryan Corcoran	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Michael Rome	Independent Director	4.3yrs	geen gegevens	0% $ 0

4.0yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van KNTE wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).

Kinnate Biopharma Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

Kinnate Biopharma Inc. Appoints Jill DeSimone as Independent Director, Effective on March 1, 2023

High number of new and inexperienced directors

High number of new and inexperienced directors

Kinnate Biopharma Inc., Annual General Meeting, Jun 10, 2022

Chief Medical Officer recently bought US$339k worth of stock

Recent updates

Kinnate Biopharma Files Form 15

Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Composite Index

Price target increased by 21% to US$4.53

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

Price target decreased by 84% to US$3.75

Insufficient new directors

Kinnate Biopharma Inc. Announces Workforce Restructuring

New minor risk - Market cap size

Price target increased by 8.1% to US$25.86

Is Kinnate Biopharma (NASDAQ:KNTE) In A Good Position To Invest In Growth?

Price target decreased by 16% to US$25.00

Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR Inhibitor

Kinnate Biopharma Inc. Appoints Jill DeSimone as Independent Director, Effective on March 1, 2023

Kinnate Biopharma Inc. to Present Trials in Progress Poster for Its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium

We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

Price target decreased to US$31.88

High number of new and inexperienced directors

Kinnate Biopharma Inc. Announces Recent Corporate Updates, Including on the Ongoing KIN-2787 Monotherapy Dose Escalation from Global Phase 1 Trial

Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-2787, an Investigational Pan-RAF Inhibitor

FDA grants fast track nod to Kinnate Biopharma's skin cancer inhibitor

Kinnate Biopharma (NASDAQ:KNTE) Is In A Good Position To Deliver On Growth Plans

Kinnate Biopharma Inc. Announces Pipeline Update

Kinnate Biopharma GAAP EPS of -$0.62 beats by $0.03

Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from Russell 2000 Growth Index

Kinnate Biopharma Inc. to Present Trial Design for its Pan-FGFR Inhibitor Product Candidate, KIN-3248, at ASCO 2022

Price target decreased to US$40.71

We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

High number of new and inexperienced directors

Kinnate Biopharma Inc., Annual General Meeting, Jun 10, 2022

Kinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of Its FGFR Inhibitor Product Candidate, KIN-3248

Kinnate Biopharma Inc. Highlights Data from its Lead RAF Candidate, KIN-2787, and RAF Clinico-Genomics Landscape Studies at the American Association for Cancer Research Annual Meeting

Price target decreased to US$43.43

Chief Medical Officer recently bought US$339k worth of stock

Kinnate Biopharma Inc. Announces Acceptance of Abstracts for Presentation At the American Association for Cancer Research Annual Meeting

Kinnate Biopharma Inc. to Deliver Oral Presentation on its RAF Inhibitor Candidate Program at the Virtual IASLC 2022 Targeted Therapies of Lung Cancer Meeting

Companies Like Kinnate Biopharma (NASDAQ:KNTE) Are In A Position To Invest In Growth

Kinnate Biopharma Inc. to Present Preclinical Data on its FGFR Inhibitor Candidate at the ASCO Gastrointestinal Cancers Symposium

Kinnate Biopharma Inc. Announces U.S Food and Drug Administration Clearance of Investigational Drug Application for KIN-3248

We Think Kinnate Biopharma (NASDAQ:KNTE) Can Afford To Drive Business Growth

Kinnate Biopharma Inc. Announces That the First Patient Has Commenced Treatment in its Phase 1 KN-8701 Clinical Trial

Here's Why We're Not Too Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Situation

Director Stephen Kaldor has left the company

Kinnate Biopharma Inc. Presents Preclinical Data From its Lead RAF Inhibitor Candidate KIN-2787 at ASCO 2021

Kinnate Biopharma Inc. to Present Pre-Clinical Data from its RAF Kinase Inhibitor Program at Annual ASCO Meeting

New 90-day low: US$29.70

We're Not Very Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Rate

Kinnate Biopharma earns bulls as IPO quiet period ends

Kinnate Biopharma Inc. has completed an IPO in the amount of $240 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd